Uppala Praveen Kumar, Karanam Sita Kumari, Kandra Naga Vishnu, Edhi Sandhya
Department of Pharmacology, Maharajah's College of Pharmacy, Vizianagaram 535002, Andhra Pradesh, India.
Department of Pharmaceutical Biotechnology, Maharajah's College of Pharmacy, Vizianagaram 535002, Andhra Pradesh, India.
World J Virol. 2025 Jun 25;14(2):103576. doi: 10.5501/wjv.v14.i2.103576.
The Marburg virus (MARV) is a dangerous infection that causes a deadly sickness known as MARV disease. This severe hemorrhagic fever is a major concern for people all over the world. Since the initial identification in 1967 during simultaneous outbreaks in Germany and Serbia, MARV has caused recurrent epidemics predominantly in sub-Saharan Africa with fatality rates ranging from 24% to 90% as a result of differences in virus strains, healthcare infrastructure, and the quality of patient treatment. Like Ebola virus, MARV causes a viral hemorrhagic fever identified in some of the same principles of clinical and epidemiological concern. However, MARV has unique biologic characteristics that require specialized research and response by public health and among researchers. Diagnosis relies on molecular tools such as real-time reverse transcriptase-polymerase chain reaction and enzyme-linked immunosorbent assay, as well as clinical and epidemiological assessments. Despite advancements in understanding MARV biology, no vaccines or antiviral therapies have been approved, with treatment limited to supportive care. Experimental therapeutics, monoclonal antibodies, RNA-based drugs, and adenovirus-based vaccines, show promise but require further validation. Current efforts in outbreak containment include surveillance, rapid diagnostics, case isolation, and safe burial practices. However, gaps in understanding MARV pathogenesis, limited diagnostic tools, and the absence of regulatory-approved vaccines underscore the urgent need for global collaboration and investment in research. Bridging these gaps is critical to mitigating the public health impact of MARV, ensuring effective response strategies for future outbreaks.
马尔堡病毒（MARV）是一种危险的传染病，可引发一种名为马尔堡病毒病的致命疾病。这种严重的出血热是全世界人们主要关注的问题。自1967年在德国和塞尔维亚同时爆发疫情时首次被发现以来，马尔堡病毒主要在撒哈拉以南非洲地区引发了反复的疫情，由于病毒毒株、医疗基础设施以及患者治疗质量的差异，病死率在24%至90%之间。与埃博拉病毒一样，马尔堡病毒会引发一种病毒性出血热，在一些临床和流行病学关注的相同原则方面有所体现。然而，马尔堡病毒具有独特的生物学特性，需要公共卫生领域以及研究人员进行专门研究并做出应对。诊断依赖于实时逆转录聚合酶链反应和酶联免疫吸附测定等分子工具，以及临床和流行病学评估。尽管在了解马尔堡病毒生物学方面取得了进展，但尚未批准任何疫苗或抗病毒疗法，治疗仅限于支持性护理。实验性治疗方法、单克隆抗体、基于RNA的药物以及基于腺病毒的疫苗显示出前景，但需要进一步验证。目前控制疫情的努力包括监测、快速诊断、病例隔离以及安全埋葬措施。然而，在理解马尔堡病毒发病机制方面存在差距、诊断工具有限以及缺乏监管批准的疫苗，凸显了全球合作和研究投资的迫切需求。弥合这些差距对于减轻马尔堡病毒对公共卫生的影响、确保未来疫情的有效应对策略至关重要。
